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ABSTRACT 29 
In late onset Alzheimer disease (AD) pathogenesis, genes, 30 
infections and immunity could be significant factors. We have 31 
reviewed if the keystone periodontal pathogen Porphyromonas 32 
gingivalis may affect genes and microglia (primary immune 33 
cells in the brain) to promote AD development. Genes for 34 
apolipoprotein, clusterin, CD33, triggering receptor expressed 35 
on myeloid cells-2 (TREM-2), tyrosine kinase binding protein 36 
(TYR-OBP), and complement receptors can affect microglia. 37 
Most of these genes can also be affected by P. gingivalis via its 38 
mastering of immune suppression. Besides, P. gingivalis can 39 
affect microglia directly in several ways. Taken together, 40 
genetic predisposition, P. gingivalis infection and microglia 41 
could promote neurodegeneration typical of that reported for 42 
AD.  43 
 44 
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1. Introduction 49 
Amyloid-beta (Aβ) plaque and phosphorylated tau (p-Tau) 50 
binding to neurofibrillary tangles (NFTs) are important 51 
neuropathological and diagnostic markers of Alzheimer’s 52 
disease (AD). Both lesions in their diverse peptide sizes (Aβ 53 
and p-Tau) can act as toxins in and outside cells in vitro and in 54 
vivo animal models [1-4]. A second factor of AD is brain 55 
infection/inflammation where the keystone pathogen in 56 
“chronic” periodontitis Porphyromonas gingivalis, seems to 57 
play an important role. Cerebral inflammation in the form of 58 
activated microglia is a third major histopathological feature, 59 
but without a role in the neuropathological diagnosis of AD.  60 
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2. Aim 61 
The aim of the present review is to discuss how genetic factors, 62 
P. gingivalis periodontal infection and microglia can interact to 63 
promote AD. Potential mechanisms for microglia affliction by 64 
P. gingivalis are listed in Table 1. 65 
 66 
3. Relationship between “chronic” periodontitis and 67 
Alzheimer’s disease 68 
Important in the relationship between “chronic” periodontitis 69 
and AD is infection where P. gingivalis is a suspect pathogen, 70 
for details, see references [3-5]. An infectious episode 71 
inevitably gives rise to inflammation (albeit acute and/or 72 
longstanding) with a degree of tissue atrophy. P. gingivalis has 73 
several virulence factors to promote brain inflammation and 74 
associated damage. 75 
 76 
3.a. Gingipains 77 
Institutionalized AD subjects show all forms of dental diseases 78 
(amongst them caries and periodontal disease), to co-exist in 79 
their dentition, and good oral health practices are unlikely to be 80 
a priority in their daily lives [6]. Recent knowledge of 81 
gingipains as virulence factors of P. gingivalis has initiated 82 
therapy towards reducing p-Tau peptide related toxicity [4]. 83 
This is being tested clinically by neutralizing P. gingivalis 84 
virulence with inhibitors of gingipains (GAIN Trial: Phase 2/3 85 
Study of COR388 in Subjects with Alzheimer's Disease. 86 
ClinicalTrials.gov Identifier: NCT03823404) [4, 7].  87 
 Gingipains of P. gingivalis are reported to digest the 88 
normal tau protein into nine fragments [4], and some of these 89 
peptides are from tau residues prone to phosphorylation and 90 
some are from two of the four microtubule binding domains 91 
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that also lie within peptides that form paired/straight helical 92 
filaments constituting NFTs [4]. This may be one pathway to 93 
releasing fragments of the tau protein into the brain’s 94 
parenchymal tissues. The extracellular phosphotau fragments 95 
generated by gingipains may be directly toxic to other neurons 96 
or the tau fragments may be of the size that neurons are able to 97 
take up at synaptic clefts during neurotransmitter uptake, 98 
thereby causing its spread from neuron to neuron. Further 99 
research is needed to clarify the role of gingipains fragmented 100 
tau peptides in the pathogenesis of AD. 101 
 102 
P. gingivalis infection promotes tau phosphorylation 103 
Gingipains have been found to be neurotoxic in vivo and in vitro, 104 
having detrimental effects on tau [4]. The capsular serotype K1 105 
P. gingivalis W83 strain has shown the potential to contribute to 106 
tau phosphorylation at Ser396 in the in vivo wild-type mouse 107 
model [8]. Furthermore, an in vitro neuronal cell line model 108 
reported by Haditsch et al. [9], demontrated an increased tau 109 
phosphorylation at Thr231 following P. gingivalis infection with 110 
persistent gingipain expression. Liu et al. [10] observed in their 111 
gingivalis-infected microglial cells towards the site of infection, 112 
activation of the phosphoinositide 3-kinase/Akt (PI3K/AKT) 113 
pathway. Our own in house data show that purified P. gingivalis 114 
lipopolysaccharide (LPS) application to a neuroblastoma cell 115 
line, in vitro cell model also activated the PI3K/AKT pathway in 116 
which glycogen synthase kinases-3 beta (GSK-3β) mRNA 117 
expression increased. The importance here is that GSK-3β is one 118 
of the enzymes that phosphorylates tau suggesting that P. 119 
gingivalis plays an important role in the NFT lesion formation 120 
and subsequent pathophysiology of AD. 121 
P. gingivalis infection promotes neurodegeneration 122 
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As mentioned, Haditsch et al. [9] reported AD-like 123 
neurodegeneration in P. gingivalis infected neurons in an in-124 
vitro culture system with persistent expression of active 125 
gingipains. Following infection with live P. gingivalis (ATCC 126 
33277) 25% of the neurons were lost in a time-dependent 127 
manner. Full length tau was reduced in surviving cells with an 128 
increase in phosphorylation over time. This finding was related 129 
to loss of neuronal synapses and was comparable to features of 130 
associated neurodegeneration together with presence of 131 
gingipains in AD autopsy brains. Accordingly, P. gingivalis 132 
can invade and survive in neurons and generate intra-neuronal 133 
gingipains that are proteolytically active, leading to 134 
neurodegeneration associated with AD. 135 
 Nonata and Nakanishi [11] found in an in vitro study 136 
that secreted gingipains from P. gingivalis induced microglial 137 
cell migration. This was likely achieved through endosomal 138 
signaling by protease-activated receptor 2 (PAR 2). 139 
Liu et al. [10], attempting to clarify the potential effects 140 
of the gingipains - Rgp and Kgp on the cellular activation of 141 
brain-resident microglia in mice, found that Rgp and Kgp 142 
cooperated thereby contributing to migration of P. gingivalis-143 
infected microglial cells towards the site of infection, and 144 
initiated expression of proinflammatory mediators by activating 145 
PAR 2. The mitogen-activated protein kinase/extracellular 146 
signal-regulated kinase (ERK) kinase/ERK pathway 147 
contributed to both cell migration and invoked an inflammatory 148 
response in microglia. Furthermore, PI3K/AKT pathway 149 
mRNA expression increased together with pro-inflammatory 150 
mediators such as IL-6, TNF-α and inducible nitric oxide 151 
synthase. The mRNA expression of the anti-inflammatory 152 
mediators interleukin 10 (IL-10), arginase-1 and IL-4 was not 153 
affected. The authors proposed that microglial cell migration 154 
was likely to have been associated with actin polymerization 155 
and may be necessary for invoking inflammatory responses in 156 
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microglia following activation of PAR 2. Further observations 157 
by Liu et al. [10] suggest and that Rgp and Kgp gingipains may 158 
be responsible for degrading components of the epithelial cell 159 
basal membrane, which may be facilitating the invasion of P. 160 
gingivalis into the brain. Liu et al. [10] experimentally tested 161 
their hypothesis by incorporating inhibitors of Rgp – KYT1 and 162 
Kgp – KYT36 and found the P. gingivalis-induced microglia 163 
cell migration was suppressed in the presence of activated PAR 164 
2 pathway. This provided poor of principle indicating that Rgp 165 
and Kgp were largely responsible for inducing migration of 166 
microglia in the brain. In the study by Dominy et al. [4] 167 
synthesized small-molecule inhibitors targeting gingipains were 168 
tested and this resulted in a reduction in the bacterial load. 169 
Furthermore, the small-molecule inhibitors of P. gingivalis 170 
reduced the extent of the brain infection established in mice. In 171 
addition, the small-molecule inhibitors blocked Aβ1-42 172 
production, diminished neuroinflammation, and rescued 173 
neurons in the hippocampus.  174 
 175 
3.b. Matrix metalloproteinases 176 
Matrix metalloproteinases (MMPs) have an important role in 177 
neuroinflammatory disorders including AD [12, 13]. Increase 178 
in the expression of MMPs in the brain tissue and blood of 179 
demented patients is reported to be part of the overall 180 
inflammatory process in AD [14]. Mroczko et al. [15] detected 181 
MMP-3 and MMP-9 localized around NFTs and Aβ plaques in 182 
AD brains. Healthy elderly with increased risk of developing 183 
AD had increased levels of MMP-3 and MMP-9 protein levels 184 
in the cerebrospinal fluid. Mroczko et al. [15] proposed that 185 
increased protein levels of these MMPs may be related to 186 
neuronal degeneration and/or formation of NFTs prior to 187 
clinical cognitive deterioration [13]. Further research is 188 
required to clarify this observation.  189 
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It is accepted that P. gingivalis can induce synthesis of 190 
MMPs in tissues and cells of the host. For example, cytokine 191 
and MMP expression in fibroblasts from peri-implantitis 192 
lesions were reported to be induced by P. gingivalis [16]. In 193 
addition, the sustained upregulation of inflammatory mediators 194 
and MMP-1 were suggested to play a role in the pathogenesis 195 
of peri-implantitis [16]. In oral squamous cell carcinoma P. 196 
gingivalis promoted invasion by induction of proMMP-9 and 197 
its activation [17]. It was suggested that P. gingivalis activated 198 
protease-activated receptor 4 (PAR4) signaling pathways, 199 
causing proMMP-9 over-expression and invasion of oral 200 
squamous carcinoma cells [18]. Since P. gingivalis does spread 201 
to the AD brain as shown experimentally in mice and in 202 
humans [4, 19] it is plausible to suggest that P. gingivalis could 203 
contribute to the pool of MMPs in the brain. 204 
 205 
3.c. Inhibitors of matrix metalloproteinases 206 
Tissue inhibitors of metalloproteinases (TIMPS) can modulate 207 
the activity of MMPs [15]. This is important because 208 
dysregulation of MMPs can lead to several disorders. In a study 209 
by Sato et al. [20], sonicated P. gingivalis extracts caused 210 
destruction of connective tissue, contributing to the process of 211 
periapical disease by activating pro-MMP-2 as well as by 212 
inactivating TIMP-1 and TIMP-2. In another study using 213 
human gingival fibroblasts, P. gingivalis LPS differentially 214 
modulated the expression of MMP-1, -2, and -3 and TIMP-1 215 
[21]. Alternatively, there is a possibility that P. gingivalis 216 
suppresses TIMPs activity in the brain, to dysregulate the MMP 217 
pool in AD patients. Again further research is warranted to 218 
clarify this possibility. 219 
 220 
4. Relationship between microglia and Alzheimer’s disease 221 
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Microglia comprise 10% of the total brain cells. They are 222 
resident macrophages and the brain’s primary innate immune 223 
cells responding to diverse stimuli (Figure 1a and b). They also 224 
act as inflammatory cells by rapidly changing morphology, 225 
proliferating and migrating to the site of infection/injury where 226 
they phagocytose and destroy invaders and remove damaged 227 
cells. Microglia secrete cytokines, chemokines, prostaglandins, 228 
nitric oxide and reactive oxygen species [22]. During aging, 229 
they develop a more inflammatory (activated) phenotype 230 
possibly due to having previously confronted diverse antigens 231 
[23], following which they may fail to return to their original 232 
resting (non-activated) state. Some microglia can survive for 233 
long periods, even more than two decades [24]. Thus, the 234 
microglial cell population in the human adult brain is 235 
characterized by a slow turnover. Their efforts to resolve any 236 
inflammatory response involves production of anti-237 
inflammatory cytokines such as IL-10. In the case of 238 
experimental oral infection with P. gingivalis in apolipoprotein 239 
E-/- (ApoE-/-) mice, the host releases copious amount of IL-10 in 240 
the serum. However, the bacterium itself still spreads to the 241 
brain and encounters microglia, which as a result become 242 
activated [25]. It appears that peripheral IL-10 mediated 243 
immune resolution in the ApoE-/- mice remains inadequate for 244 
microglia to return to the resting state [25, 26]. Recent research 245 
in mice has shown that microglia are able to “remember” a 246 
previous inflammatory challenge and become “trained” or 247 
“tolerant” to toxins like LPS [27]. This may prolong existence 248 
of the endotoxin in infected brains. Thus, immune training can 249 
inadvertently increase cerebral β-amyloidosis while tolerance 250 
may decrease it. The immune memory affects the reaction of 251 
microglia to new stimuli and the way in which they deal with 252 
toxic Aβ plaque in the brain (Figure 1b), thereby modifying 253 
neuropathology.  254 
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 It seems the severity of AD and its progression may be 255 
linked to chronic inflammation [28, 29]. It is therefore plausible 256 
to suggest that immunological memory in long-living microglia 257 
can represent a risk for not only protracting but also initiating 258 
clinical AD at the appropriate age, particularly if they become 259 
tolerant to inflammation [27]. Singhrao et al. [30] proposed that 260 
the long-term effect of inflammatory mediators, pathogens, 261 
and/or their virulence factors could, over time, prime the 262 
brain’s microglia in individuals with inherent susceptibility 263 
traits.  264 
Microglia are not uniform cells, and this is why only 265 
fragments of microglia are seen in tissue sections following 266 
their immuno/fluorescence/histochemistry reactivities (Figure 267 
1a and b). Activation of microglia in the central nervous system 268 
involves two opposing phenotypes denoted M1 and M2. 269 
Depending on the trigger that activates these two phenotypes, 270 
microglia (M1) can exert cytotoxic (proinflammatory cytokine 271 
release) or neuroprotective (M2) (immune resolution) effects 272 
[31]. Hammond et al. [32], performed single-cell RNA 273 
sequencing and in situ brain mapping, and detected nine 274 
transcriptionally distinct stages of > 76,000 microglial cells in 275 
mice expressing unique sets of genes. Some of these genes 276 
were upregulated in microglia-surrounding Aβ plaques [33]. 277 
Microglial cell phenotypes were most diverse in the developing 278 
brain and following aging and injury. Furthermore, RNA 279 
sequencing revealed that the expression of genes from 280 
microglial cell activation increased in several neurological 281 
diseases including AD [34]. 282 
Microglia can also develop functional defects as seen in 283 
other neurodegenerative disorders [Boche et al., 2013]. During 284 
early stages of AD, they play a key role in the clearance of Aβ 285 
and reducing the plaque burden [35]. However, Aβ plaques and 286 
extracellular tau peptides can eventually become surrounded by 287 
glial cells with dysfunctional homeostatic control and as a 288 
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result acquire a proinflammatory phenotype amplifying 289 
neuronal damage [36]. Similarly, cytokines and 290 
proinflammatory molecules secreted by microglia that initially 291 
have a neuroprotective role, can subsequently become the cause 292 
of further neurodegeneration [36]. If microglia become 293 
overactive, they can initiate the biosynthesis of complement 294 
proteins and with the appropriate trigger, activate the 295 
complement cascade [37]. This can lead to their aberrant 296 
digestion of nerve synapses [38]. This is observed in mice 297 
lacking the TAR DNA-binding protein 43 (TPD-43) [39]. A 298 
complement-microglial axis has been found to drive synapse 299 
loss in AD [40] and is a plausible issue for deteriorating 300 
memory.  301 
 302 
5. Relationship between P. gingivalis and microglia 303 
It is noteworthy that gingipains have been detected in microglia 304 
[8], and in the capillaries of the hippocampus in ApoE-/- mice 305 
brains that were from a mono-P. gingivalis-infected group [41]. 306 
Mice brains have shown a potent microglial activation response 307 
to mono-P. gingivalis infection [25]. However, there are also 308 
several other effects that P. gingivalis may exert on microglia, 309 
which are less appreciated.  310 
 311 
5.a. Affliction by genetic factors 312 
Genome-Wide-Association Studies (GWAS) have identified 313 
several susceptibility genes expressed by microglia in AD. 314 
Genome-wide meta-analysis of clinically diagnosed AD and 315 
AD-by-proxy (71,880 cases, 383,378 controls) found 316 
associated genes to be strongly expressed in immune-related 317 
tissues (spleen and liver), and cell types such as microglia [42]. 318 
Other GWAS and integrated network studies identified 319 
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immune-related pathways, as risk factors for AD, with 320 
microglia as central players. These studies strongly support the 321 
idea that genes, pathogens and the immune system act together 322 
in the eventual development of AD [5, 43]. Among the genes 323 
related to microglia and AD were clusterin (apolipoprotein J), 324 
complement receptor 1 (CR1), CD33, triggering receptor 325 
expressed on myeloid cells-2 (TREM-2) and tyrosine kinase 326 
binding protein (TYR-OBP) [44]. These genes play a role in 327 
clearance of cellular debris from the brain. However, in the 328 
context of P. gingivalis infection of the brain, the impressive 329 
immune subversion of this bacterium in cleaving receptors 330 
challenges this very function as discussed below. 331 
Clusterin gene 332 
The clusterin gene was identified as an important risk locus for 333 
AD with the three SNPs (rs 11136000, rs 2279590 and 334 
rs9331888) showing statistically significant relationship with 335 
the disease [45, 46]. Clusterin (CLU) is one of the complement 336 
cascade regulatory plasma proteins that significantly increases 337 
during AD [47]. It is present in Aβ plaques where it binds to 338 
insoluble amyloid peptides and interacts with Aβ40 and Aβ42 339 
[48]. Due to its well accepted role in the complement cascade, 340 
CLU is likely to affect Aβ clearance, amyloid deposition and 341 
subsequent neurotoxicity [49]. CLU is also said to stimulate 342 
expression and secretion of various chemotactic cytokines such 343 
as TNF-α, which has a critical role in promoting macrophage 344 
chemotaxis via the Pi3K/Akt mitogen-activated protein ERK 345 
and JNK pathways [50].  346 
CR1 gene 347 
It has been reported that SNPs rs3818361 and rs6656401 of the 348 
CR1 gene is associated with increased likelihood of AD [48]. 349 
This supports a CR1 gene defect in AD [5]. CR1 helps with 350 
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regulating the complement cascade and promotes phagocytosis 351 
of cellular debris and Aβ plaques, and adherence of immune 352 
complexes to erythrocytes [5]. Interestingly, P. gingivalis 353 
mediates immune subversion in relation to CR1 [51]. This may 354 
suggest that a vulnerability-axis exists, within a protein region 355 
(e.g. CR1), which is exploited by both genetic defects and 356 
pathogens like P. gingivalis. 357 
 358 
CD33 359 
CD33 appears to have an important role in Aβ clearance and 360 
other neuroinflammatory pathways in the brain aided by 361 
microglia [49]. CD33 belongs to an immunoglobulin (Ig)-like 362 
family of receptors that are expressed on myeloid cells 363 
including microglia [52, 53]. CD33 binds to alpha2-3- or 364 
alpha2-6-linked sialic acids (N-acetyl neuraminic acid) to 365 
which P. gingivalis also binds [54]. Sialylation of P. gingivalis 366 
cell surface components such as LPS may provide additional 367 
benefits to this prominent periodontal pathogen in biofilm 368 
formation and in escaping complement mediated killing [55]. 369 
CR1 is highly expressed on CD33+ cells which facilitate P. 370 
gingivalis binding to it and is also a general clearance receptor 371 
for pathogens [56]. However, P. gingivalis is either able to 372 
cleave CD33 from surface membrane of cells or down-regulate 373 
functional cell surface receptors on myeloid cells. If this was 374 
the case, then the CD33 receptor expression would be affected 375 
in a similar way on microglia. 376 
 377 
TREM-2 gene 378 
The TREM-2 gene codes for a protein in the brain that is 379 
expressed on microglial cells and is also involved in removing 380 
degenerated tissue, including remnants from 381 
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neuroinflammation [57]. The TREM-2 protein has been found 382 
to increase the susceptibility to AD, with an odds ratio similar 383 
to that of the apolipoprotein ε4 allele [58, 59]. TREM-2 384 
deficiency inhibited Aβ degradation in a primary microglial 385 
culture and in a mouse brain model [60]. Interestingly, P. 386 
gingivalis significantly down-regulated TREM-2 expression in 387 
microglia [61]. Lack of TREM-2 protein may accelerate aging 388 
processes, neuronal cell loss and reduce microglial activity 389 
leading to neuroinflammation [62].  390 
 391 
TYR-OBP gene 392 
TYR-OBP has been identified as a key regulator among genes 393 
involved in phagocytosis [63]. It is a key signaling molecule for 394 
TREM-2, as determined from networks involved in immune 395 
and microglia-specific modules disrupted in AD brains 63]. 396 
The association of this gene defect with P. gingivalis activity is 397 
little understood. Further research is needed to clarify if P. 398 
gingivalis can affect TREM-2 signaling through TYR-OBP. 399 
 400 
5.b. Complement activation 401 
P. gingivalis has been proposed to exploit complement 402 
receptors 1 and 3 for evading innate immune clearance [64, 65]. 403 
Active invasion of P. gingivalis-induced complement activation 404 
in ApoE-/- mice brains has been investigated [25]. Microglia in 405 
both infected (P. gingivalis, oral infection) and control groups 406 
exhibited strong intracellular labeling with complement 407 
components/opsonins from C3 and C9, due to on-going 408 
biosynthesis and activation. Further, Poole et al. [25] showed 409 
that P. gingivalis was able to access the ApoE-/- brain and 410 
contribute to development of AD inflammatory pathology 411 
through mechanisms involving acute-phase proteins, cytokines 412 
and the complement cascade where neurons would be attacked. 413 
It has since been shown that ApoE binds to activated C1q and 414 
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that the resulting C1q-ApoE complex becomes a common 415 
player to affect brain inflammation [66]. Thus, inappropriate 416 
complement activity plays a significant role in AD 417 
pathophysiology. Interestingly, treatment with small interfering 418 
RNA (siRNA) against C5, which is formed in all complement 419 
pathways, attenuated Aβ-associated microglia accumulation 420 
[66]. As mentioned, microglia and the complement-dependent 421 
pathway can over-prune functional synapses and lead to 422 
memory loss [44]. 423 
 424 
5.c. Activation by lipopolysaccharide 425 
LPS is one of the major virulence factors of P. gingivalis. 426 
Several animal studies have shown that LPS administered 427 
directly into the peritioneum of the brain initiates 428 
neuroinflammation in the form of microglial cell activation 429 
[e.g., 67]. Researchers measured the inflammatory response 430 
following LPS administration in experimental mice and this 431 
demonstrated learning and memory impairment in test mice 432 
[68, 69]. In the Cunningham study [67] the microglial cells 433 
were “primed” so that they induced increased inflammatory 434 
responses to subsequent LPS challenges.  435 
In a study by Henry et al. [70] peripheral LPS challenge 436 
in aged mice induced a hyperactive microglial response 437 
together with a higher induction of inflammatory IL-1β and 438 
anti-inflammatory IL-10.  Injection of LPS caused a marked 439 
induction of mRNA expression of both IL-1β and IL-10 in the 440 
cortex of aged mice as compared to adults. An age-dependent 441 
increase in the major histocompatibility complex (MHC) class 442 
II mRNA and protein expression were also seen in microglia, 443 
suggesting their activated status. Other studies have indicated 444 
that, peripheral injection of P. gingivalis LPS also causes a 445 
higher increase in IL-1β. Interestingly, the most prominent 446 
induction of IL-1β was detected in MHC II (+) microglia from 447 
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aged mice [71]. In another study Zhang et al. [72] found that P. 448 
gingivalis LPS induced cognitive dysfunction, mediated by 449 
neuronal inflammation via activation of the TLR4 signaling 450 
pathway in C57BL/6 mice. Both microglia and astrocytes in the 451 
cortex and hippocampus were activated. Accordingly, age-452 
associated priming of microglia seems to have a central role in 453 
exaggerated inflammation induced by activation of the 454 
peripheral immune system. IL-1β is also implicated in synaptic 455 
loss [73, 74], promoting deterioration in cognition [44] by 456 
stimulating Aβ cleavage indirectly from the action of cathepsin 457 
B on the APP with its cognate receptor (IL-1R) on neurons 458 
[71]. Last, but not least, P. gingivalis LPS has been reported in 459 
the human brain, thus suggesting it might activate brain 460 
microglia participating in brain inflammation [4]. This idea was 461 
supported in an 18-h in vitro stimulation study with ultrapure P. 462 
gingivalis LPS in rats that resulted in classical and alternative 463 
activation of rat brain microglia and the concomitant release of 464 
cytokines and chemokines [75]. 465 
Microglia, being influenced by their environment, can 466 
assume a diversity of phenotypes and can change functions 467 
aimed to maintain homeostasis. Like their macrophage 468 
“cousins”, microglia show unique features with regard to 469 
phenotype polarization. As mentioned, they can be stimulated 470 
by LPS and IFN-ɣ to develop into an M1 phenotype for 471 
expression of proinflammatory cytokines, or by IL-4/IL-13 to 472 
an M2 phenotype for resolution of inflammation and tissue 473 
repair [76]. Whether P. gingivalis-LPS has this capacity is not 474 
known. P. gingivalis causes an imbalance in M1/M2 activation 475 
in macrophages, resulting in a hyperinflammatory environment 476 
that promotes the pathogenesis of periodontitis [77]. These 477 
authors reported that P. gingivalis or P. gingivalis-derived LPS 478 
induced inflammatory responses that enhanced M1 479 
macrophages and suppressed M2 macrophages, even in the 480 
presence of IL-4. Interestingly, resveratrol has been found to 481 
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reduce inflammatory damage and promote microglia 482 
polarization to the M2 phenotype in LPS-induced   483 
neuroinflammation [78].  484 
 485 
5.d. Transduction of inflammatory signals to microglia by 486 
leptomeningeal cells  487 
The leptomeninges (pia mater and the arachnoid together 488 
housing the brain and spinal cord) plays a role as secretory 489 
cells, which transduce systemic inflammatory signals into the 490 
CNS [79-81]. In studies by Liu et al. [82] and Wu and 491 
Nakanishi [83] leptomeningeal cells transduced inflammatory 492 
signals from peripheral macrophages to brain-resident 493 
microglia exposed to P. gingivalis LPS. The mean amount of 494 
TNF-α and IL-1β after exposure to conditioned medium from 495 
P. gingivalis LPS-stimulated macrophages were significantly 496 
higher than after treatment with P. gingivalis LPS alone. This 497 
indicated that leptomeningeal cells could transduce 498 
inflammatory signals to microglia in the deeper brain areas, 499 
which in turn initiated neuroinflammation.  500 
 501 
5.e. Porphyromonas gingivalis DNA in brain microglia 502 
Repeated chronic oral administration of P. gingivalis in wild 503 
type mice transferred P. gingivalis to the brain where the 504 
bacterium and its proteases (gingipains) were detected within 505 
intra-nuclear and peri-nuclear locations of microglia, 506 
astrocytes, neurons, and extracellular spaces [8]. Microgliosis 507 
and astrogliosis were found in the experimental but not in the 508 
control group, and significantly higher levels of expression of 509 
IL6, TNF-α and IL-1β were detected in the experimental group. 510 
Also, neurodegeneration was more evident in the experimental 511 
group. Extracellular Aβ42 was detected in the parenchyma of 512 
the experimental group but not in controls. This was the first 513 
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report of p-Tau (Ser396) and NFT formation. Ilievski et al. [8] 514 
have proven the concept that chronic periodontal infection can 515 
result in the formation of the diagnostic neuropathology lesions 516 
consistent with AD. Haditsch et al. [9], confirmed the findings 517 
of Ilievski et al. [8] for p-Tau on Ser396 and additionally 518 
demonstrated an increased tau phosphorylation at Thr231 519 
following P. gingivalis infection with persistent gingipain 520 
expression with ongoing neurodegeneration. 521 
 522 
6. Concluding remarks 523 
GWAS have indicated that genes, pathogens and the immune 524 
system act together to generate AD. In addition, 525 
neuroinflammation plays a pivotal role and this has made 526 
scientist’s ask the question if AD is an infectious disease. In 527 
this complex interaction of different players, microglia seem to 528 
be important in the host defense against invasion of the 529 
keystone periodontopathogen P. gingivalis. The latter may 530 
affect microglia in both direct and indirect ways. Whether other 531 
putative periopathogens and even intestinal bacteria also affect 532 
microglia of the AD brain remain to be tested. Astrocytes, 533 
which are macroglia, can also be activated by P. gingivalis. 534 
Such activation may have toxic effects on neurons. The chronic 535 
nature of low-level infections such as “chronic” periodontitis 536 
and associated byproducts, e.g. endo/exotoxins and cytokines 537 
could affect susceptible brains’ defense capacity to a point 538 
where microglia involved in brain protection become adversely 539 
affected. Whether microglia will “remember” inflammation 540 
caused by P. gingivalis and develop “tolerance” to it, requires 541 
further research. However, it is plausible to suggest that once 542 
microglia are primed by P. gingivalis exposure, there remains 543 
the possibility of developing tolerance through the mastery of 544 
innate immunity manipulation by this bacterium, which may be 545 
18 
 
the result of inadequate clearance of cellular debris (Aβ) from 546 
the AD brain. 547 
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Table 1. Potential mechanisms for microglia affection by Porphyromonas gingivalis 892 
(P.g.) 893 
Factor  Mechanism     Ref 894 
Gingipains               Inhibitors of gingipains are being tested for reducing p-Tau 895 
                                toxicity in man                                                                           4 896 
                                Persistent expression of gingipains in P.g.-infected neu- 897 
                                rons gave AD-like neurodegeneration                                       8 898 
                               Secreted gingipains from P.g. induced microglia migration    11 899 
                                Inhibitors of Rgp and Kgp suppressed P.g.-induced micro- 900 
                                glia migration                                                                          10 901 
Matrix metallo- 902 
proteinases (MMPs)P.g. can induce synthesis of MMPs in host tissues and cells 16 903 
                                P.g. may contribute to the brain pool of MMPs                   4,19 904 
Inhibitors of MMPs  905 
(TIMPs)                  P.g. inactivated TIMP-1 and TIMP-2 causing destruction 906 
                                of connective tissue                                                                 20 907 
 Clusterin gene       Clusterin is a complement cascade regulatory plasma 908 
protein. P.g. phosphorylated its ser396 in mice                        8                                                        909 
CR1 gene                CR1 regulates complement cascade. P.g.causes immune 910 
                                subversion in relation to CR1                                                 51 911 
CD33                      Belongs to an Ig-like family of receptors expressed on 912 
                               microglia.CR1 and is highly expressed on CD33+ cells to 913 
                               which P. g. binds      56 914 
TREM-2 gene         Codes for a protein expressed on microglia. P.g. down-regu- 915 
                                lates TREM-2 expression on microglia which may accele- 916 
                                rate AD                  57, 58 917 
TYR-OBP gene       Key signaling molecule for TREM-2                                     63                                918 
Complement            P.g. initiated AD inflammation involving the comple- 919 
                                 ment cacade of ApoE-/- brains                                              25 920 
LPS                         Initiates neuroinflammation through microglia activation    67 921 
                                Migroglia were “primed” inducing increased responses to 922 
                                subsequent challenges                                                           67 923 
When located in brains microglia can be activated by 924 
 P.g.  LPS                                                                           4, 75                                                                                    925 
 P.g. causes imbalance in the M1/M2 phenotype of  926 
microglia                                                                                77 927 
Leptomeningeal 928 
cells                         P.g. LPS stimulated transfer of inflammatory signals from 929 
31 
 
                                peripheral macrophages to brain-resident microglia     82,83 930 
                                Administration of P.g. to mice caused P.g. and its prote- 931 
                               ases to be detected intra- and perinuclear in microglia         8 932 
 933 
       934 
                 935 
 936 
 937 
  938 
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Figure 1. Brain tissue showing microglia responding to 939 
infection in a mouse model and to Aβ plaque in a brain tissue 940 
section from Alzheimer’s disease. 941 
 942 
a) Confocal image. Brain tissue showing microglia (white 943 
arrows) following mono-P. gingivalis infection (24 weeks) 944 
from an apolipoprotein E-/- mouse brain immunolabelled to 945 
demonstrate microglia (anti-1ba1); Blue = DAPI; Red =  946 
TRITC label for immunopositive microglia. 947 
b) Immunohistochemistry. Double labelling of a cortical human 948 
AD brain tissue section showing activated microglia brown 949 
(anti-HLADR) demarcated by black arrows, and Aβ plaque 950 
(anti-Aβ) blue (white arrow head) to demonstrate their 951 
relationship.  952 
